Annemarie Eek
Overview
Explore the profile of Annemarie Eek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boss M, Eriksson O, Mikkola K, Eek A, Brom M, Buitinga M, et al.
J Nucl Med
. 2024 Oct;
65(12):1959-1964.
PMID: 39419553
Precise anatomic localization of insulinomas is crucial for surgical treatment. Current routine noninvasive imaging techniques, including CT, MRI, and Ga-DOTA-somatostatin analog (DOTA-SSA) PET/CT, have limited sensitivity. Endoscopic ultrasound is highly...
2.
Peters S, Prive B, de Bakker M, de Lange F, Jentzen W, Eek A, et al.
Eur J Nucl Med Mol Imaging
. 2021 Jul;
49(2):460-469.
PMID: 34218300
Introduction: While [Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients can benefit from it. However,...
3.
Boss M, Rottenburger C, Brenner W, Blankenstein O, Prasad V, Prasad S, et al.
J Nucl Med
. 2021 Jul;
63(2):310-315.
PMID: 34215672
Surgery with curative intent can be offered to congenital hyperinsulinism (CHI) patients, provided that the lesion is focal. Radiolabeled exendin-4 specifically binds the glucagonlike peptide 1 receptor on pancreatic β-cells....
4.
Prive B, Peters S, Muselaers C, van Oort I, Janssen M, Sedelaar J, et al.
Clin Cancer Res
. 2021 Apr;
27(13):3595-3601.
PMID: 33883176
Purpose: [Lu]Lu-PSMA-617 radioligand therapy (Lu-PSMA) is a novel treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be applied to patients with metastatic hormone-sensitive prostate cancer (mHSPC) with PSMA...
5.
Afzelius P, Heegaard P, Jensen S, Alstrup A, Schonheyder H, Eek A, et al.
Am J Nucl Med Mol Imaging
. 2020 Mar;
10(1):32-46.
PMID: 32211217
Osteomyelitis (OM) is an important cause of morbidity and sometimes mortality in children and adults. Long-term complications can be reduced when treatment is initiated in an early phase. The diagnostic...
6.
Lutje S, van Rij C, Franssen G, Fracasso G, Helfrich W, Eek A, et al.
Contrast Media Mol Imaging
. 2014 Apr;
10(1):28-36.
PMID: 24764162
D2B is a new monoclonal antibody directed against an extracellular domain of prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer. The potential of D2B IgG, and F(ab')2 and...
7.
Lutje S, Rijpkema M, Franssen G, Fracasso G, Helfrich W, Eek A, et al.
J Nucl Med
. 2014 Apr;
55(6):995-1001.
PMID: 24700882
Unlabelled: Both radionuclide imaging and near-infrared fluorescent (NIRF) imaging have a high sensitivity to detect tumors in vivo. The combination of these modalities using dual-labeled antibodies may allow both preoperative...
8.
Peters H, Laarakkers C, Pickkers P, Masereeuw R, Boerman O, Eek A, et al.
BMC Nephrol
. 2013 Mar;
14:70.
PMID: 23531037
Background: Hepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients with renal insufficiency, which may contribute to anemia. Urine hepcidin was found to be...
9.
Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A
Cancer Biother Radiopharm
. 2013 Mar;
28(3):187-95.
PMID: 23461385
Affibody molecules (6-7 kDa) are a new class of small robust three-helical scaffold proteins. Radiolabeled subnanomolar anti-HER2 affibody ZHER2:342 was developed for imaging of HER2 expression in tumors, and a...
10.
Roosenburg S, Laverman P, Joosten L, Eek A, Rutjes F, van Delft F, et al.
Mol Imaging
. 2012 Sep;
11(5):401-7.
PMID: 22954184
Cholecystokinin (CCK) receptors are overexpressed in several human tumor types, such as medullary thyroid carcinomas and small cell lung cancers. Several ligands for the CCK2 receptor (CCK2R) have been developed...